Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid.

Rauchmann BS, Sadlon A, Perneczky R; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2020 Jan 13. doi: 10.3233/JAD-191120. [Epub ahead of print]

PMID:
31958095
2.

Real-space navigation testing differentiates between amyloid-positive and -negative aMCI.

Schöberl F, Pradhan C, Irving S, Buerger K, Xiong G, Kugler G, Kohlbecher S, Engmann J, Werner P, Brendel M, Schneider E, Perneczky R, Jahn K, la Fougère C, Bartenstein P, Brandt T, Dieterich M, Zwergal A.

Neurology. 2020 Jan 2. pii: 10.1212/WNL.0000000000008758. doi: 10.1212/WNL.0000000000008758. [Epub ahead of print]

PMID:
31896617
3.

Metabolic correlates of dopaminergic loss in dementia with lewy bodies.

Huber M, Beyer L, Prix C, Schönecker S, Palleis C, Rauchmann BS, Morbelli S, Chincarini A, Bruffaerts R, Vandenberghe R, Van Laere K, Kramberger MG, Trost M, Grmek M, Garibotto V, Nicastro N, Frisoni GB, Lemstra AW, van der Zande J, Pilotto A, Padovani A, Garcia-Ptacek S, Savitcheva I, Ochoa-Figueroa MA, Davidsson A, Camacho V, Peira E, Arnaldi D, Bauckneht M, Pardini M, Sambuceti G, Vöglein J, Schnabel J, Unterrainer M, Perneczky R, Pogarell O, Buerger K, Catak C, Bartenstein P, Cumming P, Ewers M, Danek A, Levin J, Aarsland D, Nobili F, Rominger A, Brendel M.

Mov Disord. 2019 Dec 16. doi: 10.1002/mds.27945. [Epub ahead of print]

4.

Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE-ε4/TOMM40 long poly-T repeat allele variants.

Prokopenko I, Miyakawa G, Zheng B, Heikkinen J, Petrova Quayle D, Udeh-Momoh C, Claringbould A, Neumann J, Haytural H, Kaakinen MA, Loizidou E, Meissner E, Bertram L; BIOS consortium, Gveric DO, Gentleman SM, Attems J, Perneczky R, Arzberger T, Muglia P, Lill CM, Parkkinen L, Middleton LT.

Alzheimers Dement (N Y). 2019 Nov 20;5:814-824. doi: 10.1016/j.trci.2019.08.005. eCollection 2019.

5.

The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort.

von Siemens SM, Perneczky R, Vogelmeier CF, Behr J, Kauffmann-Guerrero D, Alter P, Trudzinski FC, Bals R, Grohé C, Söhler S, Waschki B, Lutter JI, Welte T, Jörres RA, Kahnert K; COSYCONET study group.

Respir Res. 2019 Nov 14;20(1):257. doi: 10.1186/s12931-019-1217-5.

6.

Prospective Evaluation of Cognitive Health and Related Factors in Elderly at Risk for Developing Alzheimer's Dementia: A Longitudinal Cohort Study.

Udeh-Momoh C, Price G, Ropacki MT, Ketter N, Andrews T, Arrighi HM, Brashear HR, Robb C, Bassil DT, Cohn M, Curry LK, Su B, Perera D, Giannakopoulou P, Car J, Ward HA, Perneczky R, Novak G, Middleton L.

J Prev Alzheimers Dis. 2019;6(4):256-266. doi: 10.14283/jpad.2019.31.

PMID:
31686098
7.

Dementia prevention and reserve against neurodegenerative disease.

Perneczky R.

Dialogues Clin Neurosci. 2019 Mar;21(1):53-60.

8.

Dementia treatment versus prevention.

Perneczky R.

Dialogues Clin Neurosci. 2019 Mar;21(1):43-51.

9.

Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid.

Takousis P, Sadlon A, Schulz J, Wohlers I, Dobricic V, Middleton L, Lill CM, Perneczky R, Bertram L.

Alzheimers Dement. 2019 Nov;15(11):1468-1477. doi: 10.1016/j.jalz.2019.06.4952. Epub 2019 Sep 5.

PMID:
31495604
10.

Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease.

Beyer L, Schnabel J, Kazmierczak P, Ewers M, Schönecker S, Prix C, Meyer-Wilmes J, Unterrainer M, Catak C, Pogarell O, Perneczky R, Albert NL, Bartenstein P, Danek A, Buerger K, Levin J, Rominger A, Brendel M.

Neuroimage Clin. 2019;24:101949. doi: 10.1016/j.nicl.2019.101949. Epub 2019 Jul 22.

11.

Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study.

Miebach L, Wolfsgruber S, Polcher A, Peters O, Menne F, Luther K, Incesoy E, Priller J, Spruth E, Altenstein S, Buerger K, Catak C, Janowitz D, Perneczky R, Utecht J, Laske C, Buchmann M, Schneider A, Fliessbach K, Kalbhen P, Heneka MT, Brosseron F, Spottke A, Roy N, Teipel SJ, Kilimann I, Wiltfang J, Bartels C, Düzel E, Dobisch L, Metzger C, Meiberth D, Ramirez A, Jessen F, Wagner M.

Alzheimers Res Ther. 2019 Jul 31;11(1):66. doi: 10.1186/s13195-019-0515-y.

12.

Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease.

Grimmer T, Goldhardt O, Yakushev I, Ortner M, Sorg C, Diehl-Schmid J, Förstl H, Kurz A, Perneczky R, Miners S.

Neurodegener Dis. 2019;19(1):43-50. doi: 10.1159/000500811. Epub 2019 Jul 2.

PMID:
31266021
13.

Cortisol, Amyloid-β, and Reserve Predicts Alzheimer's Disease Progression for Cognitively Normal Older Adults.

Udeh-Momoh CT, Su B, Evans S, Zheng B, Sindi S, Tzoulaki I, Perneczky R, Middleton LT; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019;70(2):553-562. doi: 10.3233/JAD-181030.

14.

miRNAs Identify Shared Pathways in Alzheimer's and Parkinson's Diseases.

Sadlon A, Takousis P, Alexopoulos P, Evangelou E, Prokopenko I, Perneczky R.

Trends Mol Med. 2019 Aug;25(8):662-672. doi: 10.1016/j.molmed.2019.05.006. Epub 2019 Jun 17. Review.

PMID:
31221572
15.

Determinants of self- and carer-rated quality of life and caregiver burden in Alzheimer disease.

Schumann C, Alexopoulos P, Perneczky R.

Int J Geriatr Psychiatry. 2019 Oct;34(10):1378-1385. doi: 10.1002/gps.5126. Epub 2019 May 8.

PMID:
31025764
16.

Meta-analyses identify differentially expressed micrornas in Parkinson's disease.

Schulz J, Takousis P, Wohlers I, Itua IOG, Dobricic V, Rücker G, Binder H, Middleton L, Ioannidis JPA, Perneczky R, Bertram L, Lill CM.

Ann Neurol. 2019 Jun;85(6):835-851. doi: 10.1002/ana.25490.

PMID:
30990912
17.

Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia.

Alexopoulos P, Thierjung N, Economou P, Werle L, Buhl F, Kagerbauer S, Papanastasiou AD, Grimmer T, Gourzis P, Berthele A, Hemmer B, Kübler H, Martin J, Politis A, Perneczky R.

J Alzheimers Dis. 2019;69(1):83-90. doi: 10.3233/JAD-181088.

PMID:
30909232
18.

The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease.

Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodríguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin J, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Grau S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee JH, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M.

Mol Psychiatry. 2019 Mar 21. doi: 10.1038/s41380-019-0404-6. [Epub ahead of print]

19.
20.

Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease.

Brugnolo A, De Carli F, Pagani M, Morbelli S, Jonsson C, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzezga A, van Berckel BNM, Ossenkoppele R, Didic M, Guedj E, Arnaldi D, Massa F, Grazzini M, Pardini M, Mecocci P, Dottorini ME, Bauckneht M, Sambuceti G, Nobili F.

J Alzheimers Dis. 2019;68(1):383-394. doi: 10.3233/JAD-181022.

PMID:
30776000
21.

General and abdominal adiposity and the risk of Parkinson's disease: A prospective cohort study.

Riso L, Kaaks R, Kühn T, Sookthai D, Forsgren L, Trupp M, Trichopoulou A, La Vecchia C, Karakatsani A, Gavrila D, Ferrari P, Freisling H, Petersson J, Lewan S, Vermeulen RC, Panico S, Masala G, Ardanaz E, Krogh V, Perneczky R, Middleton LT, Mokoroa O, Sacerdote C, Sieri S, Hayat SA, Brayne C, Riboli E, Vineis P, Gallo V, Katzke VA.

Parkinsonism Relat Disord. 2019 May;62:98-104. doi: 10.1016/j.parkreldis.2019.01.019. Epub 2019 Feb 8.

PMID:
30772279
22.

Exploring causality of the association between smoking and Parkinson's disease.

Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, Sieri S, Kühn T, Katzke VA, van der Schouw YT, Kyrozis A, Masala G, Mattiello A, Perneczky R, Middleton L, Saracci R, Riboli E.

Int J Epidemiol. 2019 Jun 1;48(3):912-925. doi: 10.1093/ije/dyy230.

23.

CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.

Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2019 Feb;74:182-190. doi: 10.1016/j.neurobiolaging.2018.10.022. Epub 2018 Oct 25.

PMID:
30458365
24.

A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers.

Zhang M, Ferrari R, Tartaglia MC, Keith J, Surace EI, Wolf U, Sato C, Grinberg M, Liang Y, Xi Z, Dupont K, McGoldrick P, Weichert A, McKeever PM, Schneider R, McCorkindale MD, Manzoni C, Rademakers R, Graff-Radford NR, Dickson DW, Parisi JE, Boeve BF, Petersen RC, Miller BL, Seeley WW, van Swieten JC, van Rooij J, Pijnenburg Y, van der Zee J, Van Broeckhoven C, Le Ber I, Van Deerlin V, Suh E, Rohrer JD, Mead S, Graff C, Öijerstedt L, Pickering-Brown S, Rollinson S, Rossi G, Tagliavini F, Brooks WS, Dobson-Stone C, Halliday GM, Hodges JR, Piguet O, Binetti G, Benussi L, Ghidoni R, Nacmias B, Sorbi S, Bruni AC, Galimberti D, Scarpini E, Rainero I, Rubino E, Clarimon J, Lleó A, Ruiz A, Hernández I, Pastor P, Diez-Fairen M, Borroni B, Pasquier F, Deramecourt V, Lebouvier T, Perneczky R, Diehl-Schmid J, Grafman J, Huey ED, Mayeux R, Nalls MA, Hernandez D, Singleton A, Momeni P, Zeng Z, Hardy J, Robertson J, Zinman L, Rogaeva E; International FTD-Genomics Consortium (IFGC).

Brain. 2018 Oct 1;141(10):2895-2907. doi: 10.1093/brain/awy238.

25.

[The speechless patient].

Häckert J, Falkai P, Perneczky R, Pogarell O.

MMW Fortschr Med. 2018 Sep;160(15):53-56. doi: 10.1007/s15006-018-0888-z. Review. German. No abstract available.

PMID:
30206846
26.

Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?

Beyer L, Meyer-Wilmes J, Schönecker S, Schnabel J, Brendel E, Prix C, Nübling G, Unterrainer M, Albert NL, Pogarell O, Perneczky R, Catak C, Bürger K, Bartenstein P, Bötzel K, Levin J, Rominger A, Brendel M.

Front Neurol. 2018 Jun 20;9:483. doi: 10.3389/fneur.2018.00483. eCollection 2018.

27.

Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer's Disease.

Alexopoulos P, Thierjung N, Grimmer T, Ortner M, Economou P, Assimakopoulos K, Gourzis P, Politis A, Perneczky R; The Alzheimer’s Disease Neuroimaging Initiative.

Dement Geriatr Cogn Disord. 2018;45(3-4):152-161. doi: 10.1159/000488481. Epub 2018 May 22.

28.

Population-Based Approaches to Alzheimer's Disease Prevention.

Perneczky R.

Methods Mol Biol. 2018;1750:15-29. doi: 10.1007/978-1-4939-7704-8_2.

29.

Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.

Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Perneczky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, Falkai P, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, Salloway S, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M.

Brain. 2018 Apr 1;141(4):1186-1200. doi: 10.1093/brain/awy008.

30.

Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease.

Alexopoulos P, Roesler J, Werle L, Thierjung N, Lentzari I, Ortner M, Grimmer T, Laskaris N, Politis A, Gourzis P, Kurz A, Perneczky R; Alzheimer’s Disease Neuroimaging Initiative.

J Neural Transm (Vienna). 2018 Feb;125(2):193-201. doi: 10.1007/s00702-017-1810-z. Epub 2017 Nov 15.

PMID:
29143217
31.

Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations.

Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz-Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Robinson L, Livingston G.

PLoS One. 2017 Jun 29;12(6):e0179521. doi: 10.1371/journal.pone.0179521. eCollection 2017. Review.

32.

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations.

Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz-Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L, Livingston G.

Health Technol Assess. 2017 May;21(26):1-192. doi: 10.3310/hta21260.

33.

Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer's disease.

Alexopoulos P, Gleixner LS, Werle L, Buhl F, Thierjung N, Giourou E, Kagerbauer SM, Gourzis P, Kübler H, Grimmer T, Yakushev I, Martin J, Kurz A, Perneczky R.

Eur Arch Psychiatry Clin Neurosci. 2018 Aug;268(5):519-524. doi: 10.1007/s00406-017-0815-9. Epub 2017 Jun 10.

PMID:
28602012
34.

Biomarkers and Functional Decline in Prodromal Alzheimer's Disease.

Robb C, Udeh-Momoh C, Wagenpfeil S, Schöpe J, Alexopoulos P, Perneczky R; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2017;58(1):69-78. doi: 10.3233/JAD-161162.

35.

Prioritizing problems in and solutions to homecare safety of people with dementia: supporting carers, streamlining care.

Tudor Car L, El-Khatib M, Perneczky R, Papachristou N, Atun R, Rudan I, Car J, Vincent C, Majeed A.

BMC Geriatr. 2017 Jan 19;17(1):26. doi: 10.1186/s12877-017-0415-6.

36.

TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.

van der Zee J, Gijselinck I, Van Mossevelde S, Perrone F, Dillen L, Heeman B, Bäumer V, Engelborghs S, De Bleecker J, Baets J, Gelpi E, Rojas-García R, Clarimón J, Lleó A, Diehl-Schmid J, Alexopoulos P, Perneczky R, Synofzik M, Just J, Schöls L, Graff C, Thonberg H, Borroni B, Padovani A, Jordanova A, Sarafov S, Tournev I, de Mendonça A, Miltenberger-Miltényi G, Simões do Couto F, Ramirez A, Jessen F, Heneka MT, Gómez-Tortosa E, Danek A, Cras P, Vandenberghe R, De Jonghe P, De Deyn PP, Sleegers K, Cruts M, Van Broeckhoven C, Goeman J, Nuytten D, Smets K, Robberecht W, Damme PV, Bleecker J, Santens P, Dermaut B, Versijpt J, Michotte A, Ivanoiu A, Deryck O, Bergmans B, Delbeck J, Bruyland M, Willems C, Salmon E, Pastor P, Ortega-Cubero S, Benussi L, Ghidoni R, Binetti G, Hernández I, Boada M, Ruiz A, Sorbi S, Nacmias B, Bagnoli S, Sorbi S, Sanchez-Valle R, Llado A, Santana I, Rosário Almeida M, Frisoni GB, Maetzler W, Matej R, Fraidakis MJ, Kovacs GG, Fabrizi GM, Testi S.

Hum Mutat. 2017 Mar;38(3):297-309. doi: 10.1002/humu.23161. Epub 2017 Jan 19.

37.

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.

Alexopoulos P, Werle L, Roesler J, Thierjung N, Gleixner LS, Yakushev I, Laskaris N, Wagenpfeil S, Gourzis P, Kurz A, Perneczky R; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Alzheimers Res Ther. 2016 Dec 9;8(1):51.

38.
39.

Nutrition for the ageing brain: Towards evidence for an optimal diet.

Vauzour D, Camprubi-Robles M, Miquel-Kergoat S, Andres-Lacueva C, Bánáti D, Barberger-Gateau P, Bowman GL, Caberlotto L, Clarke R, Hogervorst E, Kiliaan AJ, Lucca U, Manach C, Minihane AM, Mitchell ES, Perneczky R, Perry H, Roussel AM, Schuermans J, Sijben J, Spencer JP, Thuret S, van de Rest O, Vandewoude M, Wesnes K, Williams RJ, Williams RS, Ramirez M.

Ageing Res Rev. 2017 May;35:222-240. doi: 10.1016/j.arr.2016.09.010. Epub 2016 Oct 3. Review.

40.

How would a decision to leave the European Union affect medical research and health in the United Kingdom?

Majeed A, Hansell A, Saxena S, Millett C, Ward H, Harris M, Hayhoe B, Car J, Easton G, Donnelly CA, Perneczky R, Jarvelin MR, Ezzati M, Rawaf S, Vineis P, Ferguson N, Riboli E.

J R Soc Med. 2016 Jun;109(6):216-218. doi: 10.1177/0141076816652027. No abstract available.

41.
42.

Metabolic connectivity for differential diagnosis of dementing disorders.

Titov D, Diehl-Schmid J, Shi K, Perneczky R, Zou N, Grimmer T, Li J, Drzezga A, Yakushev I.

J Cereb Blood Flow Metab. 2017 Jan;37(1):252-262. Epub 2015 Dec 31.

43.

Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study.

Klöppel S, Peter J, Ludl A, Pilatus A, Maier S, Mader I, Heimbach B, Frings L, Egger K, Dukart J, Schroeter ML, Perneczky R, Häussermann P, Vach W, Urbach H, Teipel S, Hüll M, Abdulkadir A; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(4):939-54. doi: 10.3233/JAD-150334.

44.

Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits.

Granert O, Drzezga AE, Boecker H, Perneczky R, Kurz A, Götz J, van Eimeren T, Häussermann P.

J Nucl Med. 2015 Dec;56(12):1916-21. doi: 10.2967/jnumed.115.156067. Epub 2015 Sep 17.

45.

Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.

Alexopoulos P, Roesler J, Thierjung N, Werle L, Buck D, Yakushev I, Gleixner L, Kagerbauer S, Ortner M, Grimmer T, Kübler H, Martin J, Laskaris N, Kurz A, Perneczky R.

Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):587-97. doi: 10.1007/s00406-015-0628-7. Epub 2015 Aug 8.

PMID:
26253588
46.

Plasma Proteomics Biomarkers in Alzheimer's Disease: Latest Advances and Challenges.

Perneczky R, Guo LH.

Methods Mol Biol. 2016;1303:521-9. doi: 10.1007/978-1-4939-2627-5_32.

PMID:
26235089
47.

The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.

Lill CM, Rengmark A, Pihlstrøm L, Fogh I, Shatunov A, Sleiman PM, Wang LS, Liu T, Lassen CF, Meissner E, Alexopoulos P, Calvo A, Chio A, Dizdar N, Faltraco F, Forsgren L, Kirchheiner J, Kurz A, Larsen JP, Liebsch M, Linder J, Morrison KE, Nissbrandt H, Otto M, Pahnke J, Partch A, Restagno G, Rujescu D, Schnack C, Shaw CE, Shaw PJ, Tumani H, Tysnes OB, Valladares O, Silani V, van den Berg LH, van Rheenen W, Veldink JH, Lindenberger U, Steinhagen-Thiessen E; SLAGEN Consortium, Teipel S, Perneczky R, Hakonarson H, Hampel H, von Arnim CAF, Olsen JH, Van Deerlin VM, Al-Chalabi A, Toft M, Ritz B, Bertram L.

Alzheimers Dement. 2015 Dec;11(12):1407-1416. doi: 10.1016/j.jalz.2014.12.009. Epub 2015 Apr 30.

48.

Gaussian Mixture Models and Model Selection for [18F] Fluorodeoxyglucose Positron Emission Tomography Classification in Alzheimer's Disease.

Li R, Perneczky R, Yakushev I, Förster S, Kurz A, Drzezga A, Kramer S; Alzheimer’s Disease Neuroimaging Initiative.

PLoS One. 2015 Apr 28;10(4):e0122731. doi: 10.1371/journal.pone.0122731. eCollection 2014.

49.

Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.

Pagani M, De Carli F, Morbelli S, Öberg J, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzezga A, van Berckel BN, Ossenkoppele R, Didic M, Guedj E, Brugnolo A, Picco A, Arnaldi D, Ferrara M, Buschiazzo A, Sambuceti G, Nobili F.

Neuroimage Clin. 2014 Nov 18;7:34-42. doi: 10.1016/j.nicl.2014.11.007. eCollection 2015.

50.

Rare variants in β-Amyloid precursor protein (APP) and Parkinson's disease.

Schulte EC, Fukumori A, Mollenhauer B, Hor H, Arzberger T, Perneczky R, Kurz A, Diehl-Schmid J, Hüll M, Lichtner P, Eckstein G, Zimprich A, Haubenberger D, Pirker W, Brücke T, Bereznai B, Molnar MJ, Lorenzo-Betancor O, Pastor P, Peters A, Gieger C, Estivill X, Meitinger T, Kretzschmar HA, Trenkwalder C, Haass C, Winkelmann J.

Eur J Hum Genet. 2015 Oct;23(10):1328-33. doi: 10.1038/ejhg.2014.300. Epub 2015 Jan 21.

Supplemental Content

Loading ...
Support Center